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Watertown, MA). Patients had continuous health plan enroll-
ment for12 months before and15 months after their ﬁrst MS
prescription. The proportion of patients with MPR >85%
(appropriate compliance) and 12-month persistence rates (pro-
portion of patients with drug therapy at month 12 without a
lapse of therapy >90 d) were evaluated across 4 treatment
groups: interferon beta (IFNb)-1a subcutaneous (SC), IFNb-1a
intramuscular (IM), IFNb-1b, and glatiramer acetate (GA).
Treatment comparisons were evaluated by using Wilcoxon rank
sum and chi-square tests for continuous and dichotomous vari-
ables, respectively. RESULTS: Immunomodulating treatment was
initiated in 3195 patients (IFNb-1a SC, n = 799; IFNb-1a IM,
n = 905; IFNb-1b, n = 344, and GA, n = 1147). Sex, geographic
region, and health plan and product types were similar across
all treatment groups. Mean age was statistically higher in the
IFNb-1a IM groups vs the IFNb-1a SC and GA groups (44.9 vs
43.5 and 43.8 y, respectively, P < 0.01) but not with the IFNb-1b
group (44.4 y). Compliance (MPR  85%) was signiﬁcantly
higher with IFNb-1a SC vs IFNb-1b (49.7% vs 39.8%;
P = 0.002) but not with GA (45.7%) or IFNb-1a IM (48.1%).
IFNb-1a SC patients had a persistence rate of 60.3%, signiﬁ-
cantly higher than that of IFNb-1a IM (54.9%) and IFNb-1b
(52.9%; P < 0.03, for both) but not GA (60.5%; P = 0.936).
CONCLUSION: All 4 groups were comparable in terms of
demographic characteristics. Although differences in compliance
were less pronounced, the IFNß-1a SC and GA treatment groups
had the highest persistence rates.
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OBJECTIVE: This study examined the relationship between
medication gaps and severe MS relapses. METHODS: Subjects
were selected from the PHARMetrics database if they had at least
one MS drug (Avonex®, Betaseron®, Copaxone®, Rebif®)
claim from January 1, 2000 through December 31, 2004, and,
were continuously eligible for 24-months following their ﬁrst
disease modifying prescription (index date), in addition to
6-months prior to the index date. Subjects were excluded if the
were <18 or >65 years of age, exposed to Tysabri® after the
index date, had evidence of study medication use in a health care
facility, or lived in a long-term care facility. A severe MS relapse
was deﬁned as an “MS-related” hospitalization or emergency
room visit. Maximum gap in therapy (Maxgap), was deﬁned as
the longest continuous period with no evidence of study medi-
cation availability (based on dispensing date and days supply).
Maxgap was categorized as 0–10 days, 11–89 days, and 90+
days. Covariates included, age, gender, region, and treatment
status (new or existing), comorbidities, and therapy type (mono-
or multi-drug therapy). RESULTS: Subjects (N = 2388) had a
mean age of 43.9 years, 76.7% were new patients, 8.1% had at
least 1 severe MS relapse over the 24-month study period, and
76.4% were female. Maxgap had a signiﬁcant odds ratio (OR) of
1.925 (p = 0.007) for the 90+ day group (0–10 day reference).
Monotherapy use for the 4 study drugs was associated with
reduced risk of severe relapse (ORs between 0.450 and 0.552).
Other signiﬁcant covariates were comorbidity and East region
(ORs = 1.090 and 1.495 respectively). Age, gender, and the other
regions were not signiﬁcant at alpha = 0.05. CONCLUSION:
Gaps in MS drug therapy longer than 90 days are associated with
a higher risk of severe MS relapse compared to short or no gaps
in treatment.
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OBJECTIVE: The objective of this analysis was to evaluate the
effect of botulinum toxin type A on quality of life in patients
with cervical dystonia. METHODS: The study consisted of
a 10-week, nonrandomized, open-label period followed by
a 10-week, randomized, double-blind, placebo-controlled, mul-
ticenter, parallel-group period. Patients were randomized to
receive either botulinum toxin type A, at a dose determined by
the physician based on the patient’s established prestudy treat-
ment regimen and the patient’s presentation, or placebo. Patients
completed the SF-36 Health Survey to evaluate the following
quality of life attributes: physical functioning, role limitations
due to physical health, role limitations due to emotional prob-
lems, energy/fatigue, emotional well-being, social functioning,
pain, and general health. RESULTS: A total of 170 patients were
randomized to treatment. A signiﬁcant difference was seen in the
change from week 0 to week 6 for the physical functioning
domain in which the botulinum toxin group had a mean change
of 2.00 (improvement) and the placebo group had a mean change
of -3.03 (worsening) (P = 0.036). Botulinum toxin produced
greater improvement than placebo for all other domains except
social functioning; however, the differences between groups were
not signiﬁcantly different. Rates of adverse events were nearly
equivalent between groups (59.1% BoNT-A vs. 58.5% placebo
group). CONCLUSION: Prior literature indicates that the SF-36
is not a sensitive measure of the change in quality of life due to
treatment in the cervical dystonia population. Despite this, the
botulinum toxin type A treatment group showed signiﬁcantly
improved physical functioning. Furthermore, important trends
were identiﬁed in other domains.
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OBJECTIVE: Migraine, affecting 11% of the US population, is a
vastly under diagnosed and underreported disease. Migraine can
impact patients’ work and studies, family relationships, social
relationships and emotional well-being thus undermining quality
of life. A review of quality of life instruments in migraine is
summarized. METHODS: Review of literature using Pubmed
with combinations of search terms ‘migraine’, ‘quality of life’,
‘questionnaire’ was conducted. Articles were selected based on
measurement of disability or quality of life in migraine. Fields
extracted from articles for each instrument and on the basis of
which analyzed included name and type of instrument, appli-
cable age group, types of respondent, means of administration,
items and domains, scaling, item selection and psychometric
properties. Pediatric versions of questionnaires were not included
in the study. RESULTS: Of the instruments that were identiﬁed 3
were generic, 11 were migraine speciﬁc questionnaires for quality
of life in migraine and 3 were migraine speciﬁc questionnaires
testing patients’ response to therapy. The average age of partici-
pants ranged from 36.5 years to 44 years. The items varied in
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